General Updates

5th August 2026 To To National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), 25th floor, P. J. Towers, Mumbai – 400 051 Dalal Street, Mumbai – 400 001 Scrip Symbol: COHANCE Scrip Code – 543064 Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of USFDA Inspection We would like to inform you that the United States Food and Drug Administration (USFDA) conducted an inspection of the Company's manufacturing facility located at Pashamylaram, Hyderabad (FEI No. 1000623515) from July 27, 2026, to August 5, 2026. At the conclusion of the inspection, the Company received a Form FDA 483 containing five observations. None of the observations relate to data integrity issues. The Company is committed to maintaining the highest standards of quality and regulatory compliance. A detailed assessment of the observations is underway, and the Company is preparing a comprehensive response, including appropriate corrective and preventive actions (CAPAs), which will be submitted to the USFDA within the stipulated timeline. The Company believes that the observations are addressable and will continue to work closely and constructively with the USFDA to ensure their timely and effective resolution. The Company remains dedicated to continuous improvement across its operations and to sustaining robust quality systems that support patient safety and regulatory compliance. This is for your information and record. Thank you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K Mishra Company Secretary and Compliance Officer